Leap Therapeutics, Inc. announced new data from Part A of the DeFianCe study, a Phase 2 study evaluating DKN-01, Leap's anti- Dickkopf-1 (DKK1) antibody, in combination with standard of care bevacizumab and chemotherapy in second-line patients with advanced colorectal cancer (CRC), to be presented at the upcoming 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium taking place in San Francisco, CA and virtually on January 18-20, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.25 USD | +2.52% | +16.07% | -21.59% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.59% | 83.21M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- LPTX Stock
- News Leap Therapeutics, Inc.
- Leap Therapeutics, Inc. to Present New Clinical Data from Part A of Defiance Study At the 2024 Asco Gastrointestinal Cancers Symposium